Jéssica M. Volejnik Pino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jéssica M. Volejnik Pino has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ana Raimunda Damaso
Programa de Pós-Graduação em Nutrição, Departamento de Fisiologia, Universidade Federal de São Paulo (UNIFESP), Campus São Paulo, São Paulo 04023-061, SP, Brazil
1 shared publication - Dan Linetzky Waitzberg
Laboratório de Nutrição e Cirurgia Metabólica (LIM35), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
1 shared publication - Danielle C. Seva
Post Graduated Program of Interdisciplinary Health Sciences, Universidade Federal de São Paulo, Santos, Brazil
1 shared publication - David Thivel
Clermont Auvergne University, EA 3533, Laboratory of the Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), CRNH-Auvergne, Clermont-Ferrand, France
1 shared publication - Gabriela Cruz Pereira
Departament of Biochemistry, Federal University of Sao Paulo (UNIFESP), São Paulo, Brazil
1 shared publication - Gabriela de Oliveira Lemos
Pennington Biomedical Research Center, LSU System, Baton Rouge, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Obesity
- Vol. 2026 (1) , 2335829
Preoperative Cer(d18:1/24:0) Shows Promise as a Candidate Predictor of Plasma Lipid Phenotypes Following Roux‐en‐Y Gastric Bypass in Women: An Exploratory Analysis of the SURMetaGIT Study
Roux‐en‐Y gastric bypass (RYGB) surgery is known to improve lipid profiles in individuals with obesity, but the degree of improvement varies. Emerging evidence suggests a role for sphingolipids in modulating cholesterol metabolism. This study investigated the relationship between plasma sphingolipid changes and cholesterol improvements in women with obesity and Type 2 diabetes mellitus (T2DM) following RYGB. Patients from the SURMetaGIT study were evaluated before and 3 months after surgery. Biochemical and sphingolipid analyses, anthropometric measures, and body composition were assessed. A nonhierarchical cluster analysis assessed distinct phenotypes in response to cholesterol after surgery. The p value from multiple comparison tests was adjusted using the false discovery rate (FDR) method. A metabolite fold change [log 2 (postoperative mean/preoperative mean)] of 1.2 and an adjusted p value < 5% were considered statistically significant. A linear regression model was used to investigate the relationship between sphingolipids and cholesterol levels. Finally, a binary logistic regression model was developed to identify the predictive value of specific discriminative sphingolipids in the lipid improvement after RYGB. Distinct sphingolipid remodeling patterns were observed, with specific sphingolipids, including Cer(d18:1/24:0), SM(d18:1/22:0), and SM(d18:1/24:0), presenting a strong positive correlation with cholesterol levels, independent of weight loss and T2DM remission. The binary logistic regression showed preoperative Cer(d18:1/24:0) could be the strongest candidate predictor of plasma lipid improvement after surgery (accuracy of 78%; AUC 0.87). These findings suggest that specific sphingolipids, notably preoperative Cer(d18:1/24:0), seemed to have a potential role in predicting cholesterol improvement after RYGB. External validation in independent cohorts is warranted before clinical applicability can be established. Trial Registration: ClinicalTrials.gov identifier: NCT01251016
- 1 January 2026
- Published by Wiley in Journal of Obesity
- Vol. 2026 (1) , 2335829
Open AccessPreoperative Cer(d18:1/24:0) Shows Promise as a Candidate Predictor of Plasma Lipid Phenotypes Following Roux‐en‐Y Gastric Bypass in Women: An Exploratory Analysis of the SURMetaGIT Study
Roux‐en‐Y gastric bypass (RYGB) surgery is known to improve lipid profiles in individuals with obesity, but the degree of improvement varies. Emerging evidence suggests a role for sphingolipids in modulating cholesterol metabolism. This study investigated the relationship between plasma sphingolipid changes and cholesterol improvements in women with obesity and Type 2 diabetes mellitus (T2DM) following RYGB. Patients from the SURMetaGIT study were evaluated before and 3 months after surgery. Biochemical and sphingolipid analyses, anthropometric measures, and body composition were assessed. A nonhierarchical cluster analysis assessed distinct phenotypes in response to cholesterol after surgery. The p value from multiple comparison tests was adjusted using the false discovery rate (FDR) method. A metabolite fold change [log 2 (postoperative mean/preoperative mean)] of 1.2 and an adjusted p value < 5% were considered statistically significant. A linear regression model was used to investigate the relationship between sphingolipids and cholesterol levels. Finally, a binary logistic regression model was developed to identify the predictive value of specific discriminative sphingolipids in the lipid improvement after RYGB. Distinct sphingolipid remodeling patterns were observed, with specific sphingolipids, including Cer(d18:1/24:0), SM(d18:1/22:0), and SM(d18:1/24:0), presenting a strong positive correlation with cholesterol levels, independent of weight loss and T2DM remission. The binary logistic regression showed preoperative Cer(d18:1/24:0) could be the strongest candidate predictor of plasma lipid improvement after surgery (accuracy of 78%; AUC 0.87). These findings suggest that specific sphingolipids, notably preoperative Cer(d18:1/24:0), seemed to have a potential role in predicting cholesterol improvement after RYGB. External validation in independent cohorts is warranted before clinical applicability can be established. Trial Registration: ClinicalTrials.gov identifier: NCT01251016
- Open Access
- 17 April 2023
- Published by Wiley in International Journal of Endocrinology
- Vol. 2023, 1-12
Severe Obesity in Women Can Lead to Worse Memory Function and Iron Dyshomeostasis Compared to Lower Grade Obesity
Objective. Obesity is one of the modifiable risk factors for dementia. Insulin resistance, the abundance of advanced glycated end-products, and inflammation are some of the mechanisms associated with the lower cognitive performance observed in obesity. This study aims to evaluate the cognitive function of subjects with distinct degrees of obesity, comparing class I and II obesity (OBI/II) to class III obesity (OBIII), and to investigate metabolic markers that can distinguish OBIII from OBI/II. Study Design. This is a cross-sectional study, in which 45 females with BMI varying from 32.8 to 51.9kg/m2 completed a set of 4 cognitive tests (verbal paired-associate test, stroop color, digit span, and ToulousePieron cancellation test) and their plasma metabolites, enzymes, and hormones related to glycemia, dyslipidemia, and liver function, as well as the biomarkers of iron status, were concomitantly analyzed. Results. OBIII showed lower scores in the verbal paired-associate test compared to OBI/II. In other cognitive tests, both groups showed similar performance. OBIII presented a lower iron status compared to OBI/II based on total iron binding capacity, degree of transferrin saturation, hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin. The levels of indicators for glycemia, liver function, and lipid metabolism were similar in both groups. Analysis of plasma metabolites showed that OBIII had lower levels of pyroglutamic acid, myoinositol, and aspartic acid and higher levels of D-ribose than OBI/II. Conclusion. Iron is an essential micronutrient for several metabolic pathways. Thus, iron dyshomeostasis observed in severe obesity may aggravate the cognitive impairment by altering metabolic homeostasis and enhancing oxidative stress. These findings can contribute to searching for biomarkers that indicate cognitive performance in the population with obesity.
- 17 April 2023
- Published by Wiley in International Journal of Endocrinology
- Vol. 2023, 1-12
Open AccessSevere Obesity in Women Can Lead to Worse Memory Function and Iron Dyshomeostasis Compared to Lower Grade Obesity
Objective. Obesity is one of the modifiable risk factors for dementia. Insulin resistance, the abundance of advanced glycated end-products, and inflammation are some of the mechanisms associated with the lower cognitive performance observed in obesity. This study aims to evaluate the cognitive function of subjects with distinct degrees of obesity, comparing class I and II obesity (OBI/II) to class III obesity (OBIII), and to investigate metabolic markers that can distinguish OBIII from OBI/II. Study Design. This is a cross-sectional study, in which 45 females with BMI varying from 32.8 to 51.9kg/m2 completed a set of 4 cognitive tests (verbal paired-associate test, stroop color, digit span, and ToulousePieron cancellation test) and their plasma metabolites, enzymes, and hormones related to glycemia, dyslipidemia, and liver function, as well as the biomarkers of iron status, were concomitantly analyzed. Results. OBIII showed lower scores in the verbal paired-associate test compared to OBI/II. In other cognitive tests, both groups showed similar performance. OBIII presented a lower iron status compared to OBI/II based on total iron binding capacity, degree of transferrin saturation, hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin. The levels of indicators for glycemia, liver function, and lipid metabolism were similar in both groups. Analysis of plasma metabolites showed that OBIII had lower levels of pyroglutamic acid, myoinositol, and aspartic acid and higher levels of D-ribose than OBI/II. Conclusion. Iron is an essential micronutrient for several metabolic pathways. Thus, iron dyshomeostasis observed in severe obesity may aggravate the cognitive impairment by altering metabolic homeostasis and enhancing oxidative stress. These findings can contribute to searching for biomarkers that indicate cognitive performance in the population with obesity.